Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Both US List And Net Drug Price Increases Have Been Substantial, JAMA Study Finds

Executive Summary

A new study looks at list drug price increases and manufacturer discounts over 11 years and finds that despite significant rebates, net price increases still grew 3.5 times more than inflation.

You may also be interested in...



Rhetoric Doesn't Square With Reality, Sanofi Drug Pricing Report Says

Sanofi said the aggregate US net price of its drugs declined by 11.1% in 2019, while list prices increased 2.9%.

The Cost To Bring A New Drug To Market? $1.3bn, JAMA Study Finds

The mean R&D investment required to bring a new drug to market was $1.3bn in a new study estimating pharma R&D costs, lower than the $2.8bn frequently cited from a prior study.

A Muted J.P. Morgan, But The Focus Is Execution – And That's Good News

A lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors, but industry is confidently executing on focused strategies as it welcomes a new decade. The persistent overhang is US drug pricing and political uncertainty.

Topics

UsernamePublicRestriction

Register

SC141770

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel